Efficacy of tigecycline alone and in combination with gentamicin in the treatment of experimental endocarditis due to linezolid-resistant Enterococcus faecium

Antimicrobial Agents and Chemotherapy

Volumn 57, Issue 7, 2013, Pages 3392-3394

  Pontikis, Konstantinos ^a   Pefanis, Angelos ^b   Tsaganos, Thomas ^a   Tzepi, Ira Maria ^a   Carrer, Dionyssia Pinelopi ^a   Giamarellou, Helen ^a,c  

^a UNIVERSITY OF ATHENS   (Greece)

^b KAT HOSPITAL   (Greece)

^c HYGEIA HOSPITAL   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

AMPICILLIN; DAPTOMYCIN; GENTAMICIN; LINEZOLID; TIGECYCLINE; VANCOMYCIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBIOTIC RESISTANCE; AREA UNDER THE CURVE; ARTICLE; BACTERIAL COUNT; BACTERIAL ENDOCARDITIS; BACTERIAL LOAD; BACTERIAL STRAIN; COLONY FORMING UNIT; CONTROLLED STUDY; DRUG EFFICACY; ENTEROCOCCAL INFECTION; ENTEROCOCCUS FAECIUM; EXPERIMENTAL RABBIT; MAXIMUM PLASMA CONCENTRATION; MINIMUM INHIBITORY CONCENTRATION; MONOTHERAPY; NONHUMAN; PRIORITY JOURNAL; RELAPSE; SINGLE DRUG DOSE; TREATMENT DURATION;

ACETAMIDES; ANIMALS; ANTI-BACTERIAL AGENTS; DRUG RESISTANCE, MULTIPLE, BACTERIAL; DRUG THERAPY, COMBINATION; ENDOCARDITIS, BACTERIAL; ENTEROCOCCUS FAECIUM; GENTAMICINS; GRAM-POSITIVE BACTERIAL INFECTIONS; MICROBIAL SENSITIVITY TESTS; MINOCYCLINE; OXAZOLIDINONES; RABBITS;

EID: 84879007068     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00646-13     Document Type: Article

References (20)

1. Munita JM, Arias CA, Murray BE. 2012. Enterococcal endocarditis: can we win the war? Curr. Infect. Dis. Rep. 14:339-349.
2. Bonora MG, Solbiati M, Stepan E, Zorzi A, Luzzani A, Catania MR, Fontana R. 2006. Emergence of linezolid resistance in the vancomycinresistant Enterococcus faecium multilocus sequence typing C1 epidemic lineage. J. Clin. Microbiol. 44:1153-1155.
3. Raad II, Hanna HA, Hachem RY, Dvorak T, Arbuckle RB, Chaiban G, Rice LB. 2004. Clinical-use-associated decrease in susceptibility of vancomycin-resistant Enterococcus faecium to linezolid: a comparison with quinupristin-dalfopristin. Antimicrob. Agents Chemother. 48:3583-3585. (Pubitemid 39129367)
4. Flamm RK, Mendes RE, Ross JE, Sader HS, Jones RN. 2013. An international activity and spectrum analysis of linezolid: ZAAPS Program results for 2011. Diagn. Microbiol. Infect. Dis. pii:S0732-8893(13)00064-3. doi:10.1016/j. diagmicrobio.2013.01.025.
5. Souli M, Sakka V, Galani I, Antoniadou A, Galani L, Siafakas N, Zerva L, Fytrou H, Tsiodras S, Giamarellou H. 2009. Colonisation with vancomycin-and linezolid-resistant Enterococcus faecium in a university hospital: molecular epidemiology and risk factor analysis. Int. J. Antimicrob. Agents 33:137-142.
6. Clinical and Laboratory Standards Institute. 2006. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. Document M7-A7. Clinical and Laboratory Standards Institute, Wayne, PA.
7. National Committee for Clinical Laboratory Standards. 1999. Methods for determining bactericidal activity of antimicrobial agents. Approved standard M26-A. National Committee for Clinical Laboratory Standards, Wayne, PA.
8. Rubino CM, Bhavnani SM, Forrest A, Dukart G, Dartois N, Cooper A, Korth-Bradley J, Ambrose PG. 2012. Pharmacokineticspharmacodynamics of tigecycline in patients with community-acquired pneumonia. Antimicrob. Agents Chemother. 56:130-136.
9. Agwuh KN, MacGowan A. 2006. Pharmacokinetics and pharmacodynamics of the tetracyclines including glycylcyclines. J. Antimicrob. Chemother. 58:256-265. (Pubitemid 44294934)
10. Lefort A, Lafaurie M, Massias L, Petegnief Y, Saleh-Mghir A, Muller-Serieys C, Le Guludec D, Fantin B. 2003. Activity and diffusion of tigecycline (GAR-936) in experimental enterococcal endocarditis. Antimicrob. Agents Chemother. 47:216-222. (Pubitemid 36070367)
11. Perlman BB, Freedman LR. 1971. Experimental endocarditis. II. Staphylococcal infection of the aortic valve following placement of a polyethylene catheter in the left side of the heart. Yale J. Biol. Med. 44:206-213.
12. Caron F. 1997. Importance of using relapse studies or tests for detection of antibiotic resistance before considering that a treatment for multidrugresistant enterococcal experimental endocarditis is effective. J. Infect. Dis. 175:232-233. (Pubitemid 27020857)
13. Gavaldà J, Cardona PJ, Almirante B, Capdevila JA, Laguarda M, Pou L, Crespo E, Pigrau C, Pahissa A. 1996. Treatment of experimental endocarditis due to Enterococcus faecalis using once-daily dosing regimen of gentamicin plus simulated profiles of ampicillin in human serum. Antimicrob. Agents Chemother. 40:173-178. (Pubitemid 26019692)
14. Murphy TM, Deitz JM, Petersen PJ, Mikels SM, Weiss WJ. 2000. Therapeutic efficacy of GAR-936, a novel glycylcycline, in a rat model of experimental endocarditis. Antimicrob. Agents Chemother. 44:3022-3027.
15. Jenkins I. 2007. Linezolid-and vancomycin-resistant Enterococcus faecium endocarditis: successful treatment with tigecycline and daptomycin. J. Hosp. Med. 2:343-344. (Pubitemid 350020012)
16. Schutt AC, Bohm NM. 2009. Multidrug-resistant Enterococcus faecium endocarditis treated with combination tigecycline and high-dose daptomycin. Ann. Pharmacother. 43:2108-2112.
17. Caron F, Kitzis MD, Gutmann L, Cremieux AC, Maziere B, Vallois JM, Saleh-Mghir A, Lemeland JF, Carbon C. 1992. Daptomycin or teicoplanin in combination with gentamicin for treatment of experimental endocarditis due to a highly glycopeptide-resistant isolate of Enterococcus faecium. Antimicrob. Agents Chemother. 36:2611-2616.
18. Vouillamoz J, Moreillon P, Giddey M, Entenza JM. 2006. Efficacy of daptomycin in the treatment of experimental endocarditis due to susceptible and multidrug-resistant enterococci. J. Antimicrob. Chemother. 58: 1208-1214. (Pubitemid 44884140)
19. Entenza JM, Moreillon P. 2009. Tigecycline in combination with other antimicrobials: a review of in vitro, animal and case report studies. Int. J. Antimicrob. Agents 34:8.e1-8.e9. doi:10.1016/j.ijantimicag.2008.11.006.
20. McConeghy KW, LaPlante KL. 2010. In vitro activity of tigecycline in combination with gentamicin against biofilm-forming Staphylococcus aureus. Diagn. Microbiol. Infect. Dis. 68:1-6.